GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Benitec Biopharma Inc.
Shares of Benitec, an early-stage biotech developing gene therapy, are a highly speculative bet on its scientific platform. Their price is driven not by financial performance, but by lab news and early research results.
Share prices of companies in the market segment - Dna
Benitec Biopharma is a biotechnology company developing a new approach to treating diseases using gene silencing technology (DNA-guided RNA interference). We've classified it in the "Dna" segment. The chart below shows the overall dynamics of the cutting-edge gene therapy sector, which attracts investors with its enormous, yet risky, potential.
Broad Market Index - GURU.Markets
Benitec Biopharma is a biotech company developing gene therapy based on gene silencing (RNAi) technology for the treatment of chronic and life-threatening diseases. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BNTC - Daily change in the company's share price Benitec Biopharma Inc.
For Benitec Biopharma, a biopharmaceutical company, change_co is a measure of the sector's inherent high volatility. Each daily change reflects sensitivity to news about clinical trials of its platform. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Dna
Benitec Biopharma Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with BNTC, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Benitec is a biopharmaceutical company developing RNA interference-based drugs. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Benitec's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Benitec Biopharma Inc.
Benitec Biopharma's year-over-year performance is a story of gene therapy development based on gene silencing (RNAi). Its 12-month market cap is entirely dependent on progress in early clinical trials. Any positive data on the safety and efficacy of its approach could lead to significant growth, as it confirms the platform's potential.
Annual dynamics of market capitalization of the market segment - Dna
Benitec Biopharma Inc. is an early-stage biotech developing a new class of RNA therapeutics. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the high risks and potential for breakthroughs characteristic of this speculative sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Benitec is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its gene-silencing platform. The company's chart exists in a world of its own, where data releases are the most important events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Benitec Biopharma Inc.
The valuation of Benitec, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of preclinical and clinical trials of its unique gene silencing technology, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Dna
Benitec Biopharma Inc. is a biotech company developing a new class of gene therapy based on DNA silencing and replacement. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its unique platform for treating rare and incurable diseases is progressing through clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Benitec Biopharma is an early-stage biotech company using gene silencing technology. Its shares move not with the market, but rather on research progress news. The chart demonstrates extreme volatility and a complete dependence of monthly performance on research successes and failures.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing gene silencing (RNA interference) therapies. Its weekly stock price is highly volatile, depending on the results of preclinical and clinical trials.
Weekly dynamics of market capitalization of the market segment - Dna
Benitec Biopharma, like the entire early-stage gene therapy sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks that impact investor interest in the entire field. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Benitec Biopharma is a biotech company working in gene therapy. Its shares follow the rhythm of clinical trial news. This chart is a great way to see how its weekly fluctuations are detached from overall market trends, following their own unique trajectory.
Market capitalization of the company, segment and market as a whole
BNTC - Market capitalization of the company Benitec Biopharma Inc.
The Benitec Biopharma chart is a visualization of the risks and hopes of gene therapy. This biotech company's market cap reflects investors' faith in its unique gene silencing technology. Its volatile curve reflects early-stage research data and funding needs.
BNTC - Share of the company's market capitalization Benitec Biopharma Inc. within the market segment - Dna
Benitec Biopharma Inc. is a biotechnology company whose market share is based on its DNA silencing and replacement platform for treating genetic diseases. Its market capitalization reflects the risks and potential of this cutting-edge technology.
Market capitalization of the market segment - Dna
Benitec Biopharma is working on gene "switching off." How big is this revolutionary arena? The chart below shows the pulse of the DNA technology sector. Its extreme volatility reflects both the enormous potential for treating genetic diseases and the high risks associated with this cutting-edge science.
Market capitalization of all companies included in a broad market index - GURU.Markets
The urban dynamics of Benitec Biopharma illustrate the risks and promises of gene therapy development. This early-stage company's capitalization is a venture bet on its unique gene-silencing technology for treating rare diseases. It's a diagram full of binary outcomes: win or lose.
Book value capitalization of the company, segment and market as a whole
BNTC - Book value capitalization of the company Benitec Biopharma Inc.
For Benitec Biopharma, a company developing gene silencing technology, book value is its tangible capital, consisting primarily of intellectual property and financial reserves for R&D. The chart below shows how this scientific and financial capital has changed.
BNTC - Share of the company's book capitalization Benitec Biopharma Inc. within the market segment - Dna
Benitec Biopharma Inc. is a biotechnology company whose tangible assets are the research laboratories where its unique gene silencing and replacement technology is developed. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Dna
Benitec Biopharma is a gene therapy company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Benitec is an R&D company, its capital not in factories, but in a patented gene silencing platform.
Book value of all companies included in the broad market index - GURU.Markets
Benitec Biopharma's resources include laboratories and R&D centers for developing a DNA/RNA "silencing and replacement" platform. The chart shows how the company is building its scientific and physical capital to create a new approach to gene therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Benitec Biopharma Inc.
Benitec Biopharma is a biotech company. Its market valuation reflects pure faith in its gene therapy platform. The chart is a visualization of investors' hopes for an early-stage scientific breakthrough.
Market to book capitalization ratio in a market segment - Dna
Benitec Biopharma is a biotechnology company developing gene silencing therapies (DNA-guided RNA interference). Its valuation is based on the potential of this cutting-edge technology. The chart reflects the high risk and potential reward.
Market to book capitalization ratio for the market as a whole
Benitec Biopharma is an early-stage biotech developing gene silencing (RNAi) therapies. Its current valuation, compared to the average, is a pure bet on its scientific platform. Investors assess its potential to create a new class of drugs, which is unrelated to its current tangible assets.
Debts of the company, segment and market as a whole
BNTC - Company debts Benitec Biopharma Inc.
Benitec Biopharma is a biotechnology company developing gene silencing therapies (DNA-guided RNA interference). This chart shows the company's financial status at an early stage. It relies entirely on equity capital to fund its preclinical and early clinical trials.
Market segment debts - Dna
Benitec Biopharma is an early-stage biotech company developing therapeutics based on gene silencing technology (DNA-guided RNA interference). This chart shows how its financial structure reflects the high-risk and long-term nature of its research, funded primarily by equity rather than debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing RNA interference-based therapies. This is a cutting-edge but risky field. This chart shows how much the company relies on debt to fund its preclinical and clinical research. It is a direct measure of its financial risk on the long road to drug development.
Market segment debt to market segment book capitalization - Dna
Benitec Biopharma is a biotech company developing a novel approach to gene therapy. This chart shows the debt burden in the biotech sector. For companies in early-stage clinical trials, it is an indicator of their ability to finance their innovative and risky research programs.
Debt to book value of all companies in the market
Benitec Biopharma is a biotech company developing gene silencing (RNAi) technology for treating diseases. This is a cutting-edge but risky field. This chart of total market debt serves as an investment climate indicator, showing how willing the financial system is to finance long-term scientific research with uncertain commercial potential.
P/E of the company, segment and market as a whole
P/E - Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing RNA interference (RNAi)-based therapies that can "turn off" disease-causing genes. This chart reflects investor speculative expectations for this cutting-edge scientific platform. Its performance is entirely dependent on clinical trial success.
P/E of the market segment - Dna
Benitec Biopharma is a biotechnology company developing a new class of gene therapy based on RNA interference technology. This approach allows for the "silencing" of disease-causing genes. This chart shows the overall valuation of the DNA technology sector, reflecting how investors evaluate advanced and riskier approaches in genetic engineering.
P/E of the market as a whole
Benitec Biopharma is a biotech company developing gene silencing technology (RNAi). Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. Benitec's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Benitec Biopharma Inc.
Benitec Biopharma is a biotechnology company developing gene silencing therapies (DNA-directed RNA interference) for the treatment of chronic and life-threatening diseases. This graph reflects the risky expectations of its cutting-edge scientific platform. The company's valuation is entirely dependent on the success of its preclinical and clinical programs.
%20P%2FE%20Benitec%20Biopharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Benitec-Biopharma-Inc.&v=1772652286811 "Chart of the company's future (projected) P/E Benitec Biopharma Inc.")
Future (projected) P/E of the market segment - Dna
Benitec Biopharma is a biotech company developing gene silencing therapies (DNA-targeted RNA interference) for the treatment of chronic and life-threatening diseases. This chart reflects speculative expectations for its breakthrough technology. Comparing these forecasts with the sector reveals the market's confidence in its unique scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772652286819 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Benitec Biopharma is a biotechnology company developing a new class of gene therapy based on gene silencing. This is a cutting-edge and high-risk scientific field. This overall risk appetite determines the company's ability to attract capital for its long-term and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772652286839 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Benitec Biopharma Inc.
Benitec Biopharma Inc. is an early-stage biotechnology company developing gene silencing therapies (DNA-directed RNA interference). Its financial performance reflects research expenses. Future profitability is entirely dependent on the success of its innovative platform in clinical trials.
Profit of companies in the market segment - Dna
Benitec Biopharma is a biotechnology company developing gene silencing technology (RNA interference) for the treatment of chronic and life-threatening diseases. The company is in early-stage research. The company's profitability chart in the DNA technology sector reflects the high investor interest in breakthrough genetic technologies, despite the long and risky path to commercialization.
Overall market profit
Benitec Biopharma is a biotechnology company developing a new class of RNA interference (RNAi)-based drugs to suppress the expression of disease-causing genes. This cutting-edge scientific technology will determine the company's success based on clinical trial results and may open new approaches to treating a wide range of diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Benitec Biopharma Inc.
Benitec Biopharma is a biotechnology company developing gene silencing therapies (DNA-directed RNA interference). This chart reflects speculative expectations for its unique scientific platform. Future revenue is entirely dependent on success in clinical trials.
%20profit%20of%20the%20company%20Benitec%20Biopharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Benitec-Biopharma-Inc.&v=1772652286980 "Graph of future (projected) profit of the company Benitec Biopharma Inc.")
Future (predicted) profit of companies in the market segment - Dna
Benitec Biopharma Inc. is a biotechnology company developing gene silencing therapies (DNA-directed RNA interference). This graph shows the projected profit trajectory for the biotech sector. This data allows one to assess the potential and risks associated with this cutting-edge, yet unproven, technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772652287007 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Benitec Biopharma, a biotech company, is projected to profit from the success of its gene silencing (RNA interference) platform. This graph reflects expectations for preclinical and clinical trial results. This is a long-term, high-risk bet on a breakthrough scientific technology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772652287021 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing gene silencing (RNAi) technology. It has no product revenue. This chart shows a valuation based entirely on the scientific potential of its platform. This is a bet on the success of its approach in clinical trials.
P/S market segment - Dna
Benitec Biopharma is a biotechnology company developing a new class of gene therapy based on gene silencing (DNA-directed RNA interference). Its valuation is based on the potential of this platform. This chart shows the average valuation in the sector, reflecting investor expectations for Benitec's future revenue from its innovative therapeutic approaches.
P/S of the market as a whole
Benitec Biopharma is a biotech company developing a novel approach to treating diseases based on gene silencing using RNA interference technology. This graph, which displays the average revenue estimate for Benitec, emphasizes that its value is determined solely by the potential of its scientific platform, not by current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing gene silencing therapies (DNA-guided RNA interference). This chart reflects investor expectations for its unique scientific platform. It shows the market's assessment of the likelihood of success of its developments in treating chronic and life-threatening diseases.
%20P%2FS%20Benitec%20Biopharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Benitec-Biopharma-Inc.&v=1772652287134 "The graph of the company's future (projected) P/S Benitec Biopharma Inc.")
Future (projected) P/S of the market segment - Dna
Benitec Biopharma is a biotechnology company developing gene therapy based on gene silencing technology (DNA-directed RNA interference). This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects speculative expectations for its unique platform.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772652287153 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Benitec Biopharma is a biotech company developing gene silencing (RNA interference) therapies. Its technology is aimed at treating chronic and life-threatening diseases. The company's potential to create a fundamentally new class of drugs is part of the long-term hopes for biotech embodied in this graph.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772652287185 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing a new class of gene therapy based on gene silencing. Being in early-stage clinical trials, it has no sales revenue. This chart shows revenue from partnerships with major pharmaceutical companies.
Sales of companies in the market segment - Dna
Benitec Biopharma Inc. is a biotechnology company developing a novel approach to gene therapy based on gene silencing using DNA-directed RNA interference (ddRNAi). This chart shows overall pharmaceutical sales, reflecting cutting-edge research in genetic medicine that could lead to new treatments.
Overall market sales
Benitec Biopharma is a biotechnology company developing RNAi-based gene silencing therapies for chronic and life-threatening diseases. This overall economic activity chart is important for Benitec through the lens of funding. Access to capital is critical for early-stage companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Benitec Biopharma Inc.
Benitec Biopharma is a biotechnology company developing a new class of drugs based on gene silencing (DNA-directed RNA interference). This chart reflects analysts' speculative expectations for the success of its unique scientific platform in developing treatments for a variety of diseases, from viral to neurological.
%20sales%20of%20the%20company%20Benitec%20Biopharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Benitec-Biopharma-Inc.&v=1772652287439 "Schedule of future (projected) sales of the company Benitec Biopharma Inc.")
Future (projected) sales of companies in the market segment - Dna
Benitec Biopharma Inc. is a biotechnology company developing gene therapies based on RNA silencing technology. This chart shows projected revenues for the entire biotech sector. While it reflects overall industry sentiment, for Benitec, the clinical success of its unique therapeutic platform is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772652287451 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Benitec Biopharma is an early-stage biotech company developing gene silencing technology. Its value is entirely dependent on the success of its scientific developments and its ability to attract funding. This chart, reflecting the investment climate, is important for Benitec. During periods of growth and increased risk appetite, early-stage companies find it easier to raise capital.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772652287501 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Benitec Biopharma Inc.
Benitec Biopharma is a clinical-stage biotech company using cutting-edge gene-freezing technology. The chart for such a company illustrates not profit, but rather capital management efficiency. It shows how the company spends investor funds on research, striving to commercialize its platform.
Market segment marginality - Dna
Benitec Biopharma is a biotechnology company developing a novel gene therapy approach that silences disease-causing genes. This chart depicts its operational structure during preclinical and early clinical trials. It highlights the significant R&D expenditures required to validate this cutting-edge technology.
Market marginality as a whole
Benitec Biopharma is a biotechnology company developing a new class of RNA interference-based drugs. Its future profitability depends on the success of its innovative scientific platform in clinical trials. This total market return chart highlights the high-risk and potentially high-reward nature of biotechnology, where Benitec aims to treat diseases at the genetic level.
Employees in the company, segment and market as a whole
Number of employees in the company Benitec Biopharma Inc.
Benitec Biopharma is a biotech company developing gene silencing therapies (DNA-guided RNA interference). This graph shows a very small team of scientists. A small staff is typical for a company in early clinical development that heavily relies on outsourcing.
Share of the company's employees Benitec Biopharma Inc. within the market segment - Dna
This graph highlights Benitec Biopharma's cutting-edge scientific approach. The company's biotech team is focused on developing gene silencing therapies (DNA-directed RNA interference). This team of scientists is working to develop a method for silencing disease-causing genes directly at the DNA level.
Number of employees in the market segment - Dna
Benitec Biopharma is a biotechnology company developing gene silencing (RNA interference) therapies. This technology enables the "silencing" of disease-causing genes. This graph illustrates how deeply science is penetrating the mechanisms of life, creating a demand for molecular biologists and geneticists working at the cutting edge of science.
Number of employees in the market as a whole
Benitec Biopharma Inc. is a biotechnology company developing gene therapy. Its future depends entirely on the success of its research programs. This general work schedule has no bearing on its activities, which are focused on developing breakthrough treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Benitec Biopharma Inc. (BNTC)
Benitec Biopharma is a biotech company developing gene silencing therapies (DNA-guided RNA interference). This chart shows its scientific potential. The astronomical market capitalization per scientist reflects investors' faith in the company's breakthrough technology, which could lead to a new class of drugs.
%20of%20the%20company%20Benitec%20Biopharma%20Inc.%20(BNTC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Benitec-Biopharma-Inc.-BNTC&v=1772652287644 "Chart of market capitalization per employee (in thousands of dollars) of the company Benitec Biopharma Inc. (BNTC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Benitec Biopharma is a biotech company developing gene silencing therapies (DNA-guided RNA interference). Its value lies in its scientific platform. This chart illustrates the enormous potential value investors see in this cutting-edge technology for treating chronic and life-threatening diseases.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772652287658 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Benitec Biopharma Inc. is a biotech company developing gene silencing technology (DNA-directed RNA interference). This chart reflects the market valuation of its scientific platform. The very high cost per employee reflects a bet that its unique approach will lead to the development of new treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772652287665 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Benitec Biopharma Inc. (BNTC)
Benitec Biopharma (BNTC) is a clinical-stage biotech company developing gene silencing (RNA interference) technology for the treatment of rare diseases. The company is not profitable. This chart shows the net loss (R&D costs) per scientist working on this complex technology.
%20Chart%20Benitec%20Biopharma%20Inc.%20(BNTC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Benitec-Biopharma-Inc.-BNTC&v=1772652287709 "Company Profit Per Employee (in thousands of dollars) Chart Benitec Biopharma Inc. (BNTC)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Benitec Biopharma is a biotech company developing gene therapy based on gene silencing (RNAi). It focuses on rare diseases. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company invests in its scientists to advance its unique, yet risky, technological platform.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772652287740 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Benitec Biopharma (BNTC) is a clinical-stage biotech company developing gene-silencing therapies for rare diseases. Like other R&D biotech companies, this chart shows the company's per-employee cost. It reflects how much the company spends on each scientist in the lab and clinical settings trying to prove the efficacy of its drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772652287777 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Benitec Biopharma Inc. (BNTC)
Benitec Biopharma is a biotech company developing RNA interference-based therapies. This chart reflects the company's preclinical activities. Revenue per employee is virtually nonexistent, as all efforts are focused on research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Benitec-Biopharma-Inc.-BNTC&v=1772652287790 "Sales chart per company employee Benitec Biopharma Inc. (BNTC)")
Sales per employee in the market segment - Dna
Benitec Biopharma is a biotech company developing gene silencing (RNA interference) therapies. This chart shows the average revenue per employee in this segment. For a clinical-stage company, this is a benchmark for productivity in a sector where success depends on R&D.
Sales per employee for the market as a whole
Benitec Biopharma is a clinical-stage biotechnology company developing gene silencing (RNAi) technology for the treatment of various diseases. They have no commercial products. This figure would be zero, as their scientific team is entirely focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Benitec Biopharma Inc. (BNTC)
Benitec Biopharma is an early-stage biotech company working in the field of gene silencing (RNAi). The bearish sentiment seen in this chart is a standard bet against speculative biotech. Bears point to a lack of revenue, high cash burn, and a low probability of clinical trial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Benitec-Biopharma-Inc.-BNTC&v=1772652287854 "Short Shares Chart for the Company Benitec Biopharma Inc. (BNTC)")
Shares shorted by market segment - Dna
Benitec Biopharma is an early-stage biotech company developing gene-freezing technology (DNA-directed RNA interference) for the treatment of rare diseases. This chart reflects the overall sentiment in the sector. It reflects the extreme investor skepticism toward biotech companies whose technologies are in the very early, preclinical stage.
Shares shorted by the overall market
Benitec Biopharma (BNTC) is an early-stage biotech company developing gene therapy. This is one of the riskiest areas in science. This chart is an indicator of risk appetite. When it rises, investors panic and flee the stock, which is essentially a research project with minimal chance of commercial success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Benitec Biopharma Inc. (BNTC)
Benitec Biopharma develops RNA interference (RNAi) therapies. The stock is highly speculative and dependent on R&D. This chart can soar above 70 on positive trial data, indicating euphoria. Oversold territory (<30) often reflects setbacks, delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Benitec-Biopharma-Inc.-BNTC&v=1772652287994 "RSI 14 indicator chart for the company's stock Benitec Biopharma Inc. (BNTC)")
RSI 14 Market Segment - Dna
Benitec (BNTC) is a biotech company working on gene silencing (RNAi) to treat incurable diseases. The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is BNTC's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Benitec (BNTC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BNTC (Benitec Biopharma Inc.)
Benitec Biopharma (BNTC) is a biotech company developing gene silencing technology (RNA interference) for the treatment of rare diseases. This chart shows the average target price. It reflects analysts' speculative assessment of the potential of this scientific platform and early trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BNTC-Benitec-Biopharma-Inc.&v=1772652288028 "A chart showing analyst consensus forecasts for the expected stock price. BNTC (Benitec Biopharma Inc.)")
The difference between the consensus estimate and the actual stock price BNTC (Benitec Biopharma Inc.)
Benitec (BNTC) is a biotech company developing genetic drugs. Its ddRNAi (DNA-directed RNA interference) platform aims to permanently disable bad genes. This is an R&D bet. This chart shows the difference between the consensus forecast and the price, reflecting analysts' belief in this futuristic science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BNTC-Benitec-Biopharma-Inc.&v=1772652288053 "A chart showing the difference between the consensus forecast and the actual stock price. BNTC (Benitec Biopharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Benitec Biopharma (BNTC) is a biotech company developing gene silencing technology (ddRNAi) for the treatment of rare diseases, beginning with oculomotor dystrophy. This chart shows general expectations for the DNA technology sector, reflecting experts' confidence in the potential of this unique R&D platform.
Analysts' consensus forecast for the overall market share price
Benitec Biopharma is a biotech company working on "gene silencing" (DNA-directed RNA interference, or DD-RNAi). Their goal is to "turn off" disease-causing genes. This chart shows overall market sentiment. For Benitec, a "science" R&D startup, how overall risk appetite (sentiment) influences funding for their risky but breakthrough platform is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Benitec Biopharma Inc.
Benitec is a biotech company working at the forefront of genetics. They use DNA-directed RNA interference (ddRNAi)—a method for disabling disease-causing genes with a single injection. This graph is a pure R&D bet. It likely reflects the market's confidence in their unique yet complex scientific platform and their early clinical data.
AKIMA Market Segment Index - Dna
Benitec (BNTC) is a clinical-stage biotech and a pioneer in gene therapy; the company is developing a unique R&D platform (gene silencing) for the treatment of rare diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (BNTC) differentiate it from the average pharma company?
The AKIM Index for the overall market
Benitec Biopharma is a biotech company developing gene silencing (ddRNAi) therapies for chronic and life-threatening diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative early-stage scientific story compares to overall economic trends.
